Type to search

Elizabeth Budde

Share
Elizabeth Budde
Haematologic Oncologist and Associate Professor
City of Hope

Elizabeth Budde

Elizabeth Budde, M.D., Ph.D. is a well-recognized clinical expert and researchers in the area of blood cancers. Her academic and clinical interests center on novel treatment for patients with lymphoma and leukemia. As a physician scientist, she leads a group of researchers in her laboratory designing and investigating the use of immunotherapy to treat blood cancers and other diseases.

She leads the Immunotherapy Modality Team and chairs the Clinical Cellular Immunotherapy Committee at the institution. She also serves as a member on several national committees including National Comprehensive Cancer Network (NCCN) guidelines for B Cell Lymphoma, NCCN guidelines for Management of Immunotherapy-related Toxicities, and Alliance of American Cancer Institute CAR T Working Group.

Dr. Budde has received many honors and awards for her work. She was chosen as a Special Fellow in Clinical Research awardee by The Leukemia & Lymphoma Society, and an awardee of the Stop Cancer Foundation seed grant in 2016. She is also a recipient of the prestigious Damon Runyon Cancer Research Foundation Clinical Investigator Award (2014-2019). She has published many peer-reviewed articles that have been featured in prominent journals including the Journal of Clinical Oncology, Blood, Clinical Cancer Research, Journal of Immunology.  She has also given many invited presentations at national and international meetings on her work.

Dr. Budde holds patents for new drugs currently under development in lymphoma and leukemia. She is the principal investigator of innovative translational research protocols and maintains a dynamic portfolio of clinical trials. Dr. Budde is devoted to making promising new treatments available to all her patients.

Posts Featuring Elizabeth Budde


Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: addcslashes() expects parameter 1 to be string, array given in /home/customer/www/pharmtechfocus.com/public_html/wp-includes/wp-db.php on line 1539
European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma | Pharmtech Focus

European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma